S
Sverre E. Kjeldsen
Researcher at University of Oslo
Publications - 771
Citations - 95426
Sverre E. Kjeldsen is an academic researcher from University of Oslo. The author has contributed to research in topics: Blood pressure & Left ventricular hypertrophy. The author has an hindex of 94, co-authored 735 publications receiving 89059 citations. Previous affiliations of Sverre E. Kjeldsen include University of Michigan & Cornell University.
Papers
More filters
Journal ArticleDOI
The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients.
Gisli Jonsson,Michael Abdelnoor,Ingebjørg Seljeflot,Harald Arnesen,Arne T. Høstmark,Sverre E. Kjeldsen,Ingrid Os,Arne Westheim +7 more
TL;DR: Results indicate that carvedilol has a more pronounced antioxidative effect than atenolol in post-AMI patients, which might be of clinical importance.
Journal ArticleDOI
Increased hematocrit before blood pressure in men who develop hypertension over 20 years.
Arne Strand,Helga Gudmundsdottir,Aud Høieggen,Eigil Fossum,Reidar Bjørnerheim,Ingrid Os,Sverre E. Kjeldsen +6 more
TL;DR: Hct was elevated at baseline compatible with the hypothesis that pathogenic hemorheological processes could be activated at the outset and prior to cardiac changes in men who later develop hypertension.
Journal ArticleDOI
Contrasting Effects of Epinephrine on Forearm Hemodynamics and Arterial Plasma Norepinephrine
Sverre E. Kjeldsen,Sverre E. Kjeldsen,Jurij Petrin,Jurij Petrin,Alan B. Weder,Alan B. Weder,Stevo Julius,Stevo Julius +7 more
TL;DR: In the present study an intravenous infusion of 0.01 micrograms/kg/min epinephrine for 10 min in healthy men has, despite its ability to increase sympathetic drive, a regional vasodilating effect in the human forearm.
Journal ArticleDOI
Serum Phosphate, Blood Pressure, and the Metabolic Syndrome—20-Year Follow-Up of Middle-Aged Men
TL;DR: In the group as a whole and in those in whom hypertension developed, there was a significant negative relationship between S‐phosphate at baseline and mean blood pressure (MBP) at follow‐up, which may suggest a role of low S‐ phosphate in the development of hypertension and the metabolic syndrome.
Journal ArticleDOI
A Case for Less Intensive Blood Pressure Control: It Matters to Achieve Target Blood Pressure Early and Sustained Below 140/90 mmHg
Julian E. Mariampillai,Per Anders Eskås,Sondre Heimark,Sverre E. Kjeldsen,Sverre E. Kjeldsen,Krzysztof Narkiewicz,Giuseppe Mancia +6 more
TL;DR: Assessment of large, randomized, and controlled trials on BP targets, as well as selected observational analyses from other large randomized BP trials, indicate the best preventive effect when achieving early and sustained BP control rather than low targets.